AbCellera Biologics (ABCL) director adds 46,387 shares in open-market buy

Rhea-AI Filing Summary

AbCellera Biologics Inc. director Michael R. Hayden reported an indirect open-market purchase of 46,387 Common Shares of AbCellera on August 12, 2026 at a weighted-average price of $10.37 per share, with individual trade prices ranging from $10.25 to $10.45.

The acquired shares are held by Genworks 2 Consulting, Inc., over which Hayden’s spouse has sole voting and investment power. Hayden reports 1,319,784 Common Shares held indirectly through Genworks 2 following the transaction and separately 118,245 Common Shares held indirectly by his spouse, and disclaims beneficial ownership of these securities except for any indirect pecuniary interest.

Insider Trade Summary

Net Buyer: 46,387 shares

Net Buy 2 txns

Insider Hayden Michael R

Role Director

Bought 46,387 shs ($481K)

Type	Security	Shares	Price	Value
Purchase	Common Shares F1, F2	46,387	$10.37	$481K
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 1,319,784 shares (Indirect, See footnote); Common Shares — 118,245 shares (Indirect, By spouse)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
2. F2. These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

Key Figures

Shares purchased: 46,387 Common Shares Weighted-average purchase price: $10.37 per share Indirect holdings via Genworks 2: 1,319,784 Common Shares +1 more

4 metrics

Shares purchased 46,387 Common Shares Indirect open-market purchase on August 12, 2026

Weighted-average purchase price $10.37 per share Common Shares purchased on August 12, 2026; trades ranged $10.25–$10.45

Indirect holdings via Genworks 2 1,319,784 Common Shares Indirect Common Shares held after the reported purchase

Indirect holdings by spouse 118,245 Common Shares Common Shares reported as held indirectly by spouse

Key Terms

weighted-average price, indirect pecuniary interest, disclaims beneficial ownership, sole voting and investment power

4 terms

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

indirect pecuniary interest financial

"except to the extent of his indirect pecuniary interest, if any, therein."

disclaims beneficial ownership financial

"The reporting person disclaims beneficial ownership of such securities, except to the extent"

sole voting and investment power financial

"The Reporting Person's spouse has sole voting and investment power with respect to the shares"

FAQ

What insider share purchase did AbCellera Biologics Inc. (ABCL) report for Michael R. Hayden?

AbCellera director Michael R. Hayden reported buying 46,387 Common Shares on August 12, 2026 at a weighted-average price of $10.37 per share, with individual trades executed between $10.25 and $10.45.

At what price range were Michael R. Hayden’s AbCellera (ABCL) shares purchased?

The reported weighted-average purchase price was $10.37 per share. The 46,387 AbCellera Common Shares were acquired in multiple transactions, with individual trade prices ranging between $10.25 and $10.45 per share.

How many AbCellera (ABCL) shares does Michael R. Hayden indirectly hold after this transaction?

Following the reported purchase, Hayden shows 1,319,784 Common Shares held indirectly through Genworks 2 Consulting, Inc., and an additional 118,245 Common Shares held indirectly by his spouse, both reported as indirect holdings.

Who has voting and investment power over the AbCellera (ABCL) shares held by Genworks 2 Consulting, Inc.?

Hayden’s spouse has sole voting and investment power over the AbCellera shares held by Genworks 2 Consulting, Inc.. Hayden disclaims beneficial ownership of these securities except to the extent of any indirect pecuniary interest.

Is Michael R. Hayden’s AbCellera (ABCL) share purchase linked to a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not selected, and there is no footnote referencing a trading plan, so the reported 46,387-share purchase is not described as made under a pre-arranged 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 11:50 AM Accepted by SEC EDGAR 08/14/2026 - 11:50 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hayden Michael R

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/12/2026		P	V	46,387	A	$10.37(1)	1,319,784	I(2)	See footnote
Common Shares								118,245	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

2. These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

Remarks:

	Tryn Stimart, attorney-in-fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)